What if veterinarians could apply advances in human health to provide better therapeutic options for dogs and cats? At Aratana Therapeutics, we’re asking more than “what if” — we’re asking how and when. As a new kind of animal health company, our sole focus is on how to solve unmet and underserved medical needs in pets with serious diseases. We are working to bring together the intersection of advances in human biotechnology and veterinary medicine to develop solutions with the goal to help raise the standard of care for medical conditions in pets.
As we hope our portfolio indicates, we’re passionate about giving veterinarians, pet owners and their pets therapeutic options based on cutting-edge science, as well as proven safety and effectiveness studies in pets. We are committed to evidence-based medicine. We run pilot and pivotal studies and analyze data to evaluate both the safety and efficacy of novel therapeutics that have the potential to give pets with serious conditions a new beginning. Ultimately, these studies are crucial in helping to improve medical treatments and outcomes for pets.
Aratana has specialized experience to move new pet therapeutics through the process of formulation development, pre-clinical and clinical evaluation, regulatory approval, manufacturing and commercialization. In addition to our approved or licensed therapeutics, we have several novel therapeutics in development for pain, viral diseases, allergy and cancer that have the potential to improve the quality of lives for dogs and cats.
Take a look at our exciting portfolio that includes our FDA-approved therapeutics and investigational therapeutic candidates.
What if veterinarians had more options to ease pain in pets? Aratana continues to explore innovative therapeutic options to offer relief for pets living in pain. Examples of the new classes of therapeutics include allogeneic stem cell therapy, which we hope continues to raise the standard of care for dogs living with osteoarthritis.
Currently, we have an FDA-approved therapeutic for the control of pain and inflammation associated with osteoarthritis in dogs and an FDA-approved long-acting, local post-operative analgesic for cranial cruciate ligament surgery in dogs.
Many cats suffer from viral infections. There are many viruses that can have very serious consequences if left untreated. Despite the incidence of these viral diseases, there is currently a lack of antiviral drugs available for veterinarians. While antiviral vaccines may prevent infection or help reduce the severity of symptoms, they do not cure a pet that is already infected. A new generation of antiviral therapeutics is needed to help improve the clinical outcome for affected pets.
What if veterinarians could give families more quality time with a pet they love?
Cancer is a devastating disease not only for humans, but for pets as well. Research shows approximately 25 percent of all dogs will die as a result of cancer and veterinarians agree better therapies are needed to help manage cancer in dogs.¹
Lymphoma is one of the most common cancers in dogs and often progresses rapidly.2 Osteosarcoma is the most common bone tumor found in dogs – it’s extremely aggressive and has a tendency to spread rapidly into other parts of the dog’s body. Without effective treatment, the prognosis for the dog tends to be poor.3
1. “Learning From Dogs with Cancer.” New York Times. http://well.blogs.nytimes.com/2015/10/21/learning-from-dogs-with-cancer/?_r=0
2. “Lymphoma in Dogs.” PetMD.com. http://www.petmd.com/dog/conditions/cancer/c_dg_lymphoma
3. “Bone Cancer in Dogs.” American Kennel Club Canine Health Foundation. http://www.akcchf.org/canine-health/your-dogs-health/bone-cancer-in-dogs.html?referrer=https://www.google.com/
Atopic dermatitis, also known as atopy, is a common allergic skin disease in dogs. In fact, this chronic type of dermatitis is one of the top five most common diagnoses in dogs.1
Unfortunately, the clinical signs of atopic dermatitis may be treated, but not cured and can severely impact the quality of life for both pets and their families.¹ It can be overwhelming for families who live with a pet suffering from atopic dermatitis, as frequent visits to the veterinarian and multiple types of treatments are often needed.
Research on the pathogenesis of atopic dermatitis continues to change perceptions and advance understanding, but there is still much to learn about this condition and its complexity. Studies in both human and animal health point toward genetic and environmental factors as likely causes. However, irritants, allergens and stress may also play a role in disease development. Veterinary dermatologists agree there is a need for more effective treatments and would welcome a therapy to treat the disease, particularly in severely affected pets.
1. “Atopic Dermatitis Causes, Symptoms and Treatments.” PetMD.com. http://www.petmd.com/dog/conditions/skin/c_dg_atopic_dermatitis
Food and Drug Administration (FDA) Center for Veterinary Medicine (CVM) Regulated Therapeutics
- GALLIPRANT® (grapiprant tablets) for the control of pain and inflammation associated with osteoarthritis in dogs
- ENTYCE® (capromorelin oral solution) for appetite stimulation in dogs
- AT-002 management of weight loss in CKD cats
- NOCITA® (bupivacaine liposome injectable suspension) for local post-operative analgesia for cranial cruciate ligament surgery in dogs
- AT-003 post-operative pain in cats
- AT-006 feline herpes virus
- AT-016 allogeneic stem cell for osteoarthritis in dogs
- AT-018 atopic dermatitis in dogs
United States Department of Agriculture (USDA) Center for Veterinary Biologics (CVB) Regulated Therapeutics
- TACTRESS® (Canine Lymphoma Monoclonal Antibody) as an aid in the treatment of dogs with T-cell lymphoma
- BLONTRESS® (Canine Lymphoma Monoclonal Antibody) as an aid in the treatment of dogs with B-cell lymphoma
- AT-014 canine osteosarcoma vaccine for dogs
This information reflects public disclosure current as of August 4, 2017.
IMPORTANT SAFETY INFORMATION
GALLIPRANT® (grapiprant tablets) is not for use in humans. For use in dogs only. Keep this and all medications out of reach of children and pets. Store out of reach of dogs and other pets in a secured location in order to prevent accidental ingestion or overdose. Do not use in dogs that have a hypersensitivity to grapiprant. If Galliprant is used long term, appropriate monitoring is recommended. Concomitant use of Galliprant with other anti-inflammatory drugs, such as COX-inhibiting NSAIDs or corticosteroids, should be avoided. Concurrent use with other anti-inflammatory drugs or protein-bound drugs has not been studied. The safe use of Galliprant has not been evaluated in dogs younger than 9 months of age and less than 8 lbs (3.6 kg), dogs used for breeding, pregnant or lactating dogs, or dogs with cardiac disease. The most common adverse reactions were vomiting, diarrhea, decreased appetite, and lethargy. Click here for full prescribing information.
ENTYCE® (capromorelin oral solution) is for use in dogs only. Do not use in breeding, pregnant or lactating dogs. Use with caution in dogs with hepatic dysfunction or renal insufficiency. Adverse reactions in dogs may include diarrhea, vomiting, polydipsia, and hypersalivation. Should not be used in dogs that have a hypersensitivity to capromorelin. Please see the full Prescribing Information for more detail.
NOCITA® (bupivacaine liposome injectable suspension) is for use in dogs only. Do not use in dogs younger than 5 months of age, dogs used for breeding, or in pregnant or lactating dogs. Do not administer by intravenous or intra-arterial injection. Adverse reactions in dogs may include discharge from incision, incisional inflammation and vomiting. Avoid concurrent use with bupivacaine HCI, lidocaine or other amide local anesthetics. Please see the full Prescribing Information for more detail.